Development of an EORTC Quality of Life Module for Renal Cell Cancer Patients: Phase I by L. Wintner, E. Beisland, C. Beisland, M. Van Hemelrijck, B. Holzner

Get full text

Radical treatment for high-risk prostate cancer among older men in Sweden according to life expectancy estimates by K. Beckmann, J. Adolfsson, M. Van Hemelrijck, D. Robinson, P. Stattin, H. Garmo

Get full text

Radiotherapy treatment for prostate cancer in Sweden: Patterns over 20 years by K. Beckmann, H. Garmo, M. Van Hemelrijck, P. Nilsson, I. Franck Lissbrant, P. Stattin

Get full text

Evaluating the performance of temporal pattern discovery: new application using statins and rhabdomyolysis in OMOP databases by M. Lavallee, T. Yu, L. Evans, M. Van Hemelrijck, C. Bosco, A. Golozar, A. Asiimwe

Get full text

The effect of active surveillance on patient-reported erectile and urinary function. Results of the Movember Foundation’s GAP3 cohort by T. Crump, S. Remmers, M. Van Hemelrijck, J. Helleman, D. Nieboer, M.J. Roobol, L.D.F. Venderbos

Get full text

Spironolactone use is associated with lower risk of prostate cancer by K. Beckmann, H. Garmo, B. Lindahl, L. Holmberg, P. Stattin, J. Adolfsson, K. Cruickshank, M. Van Hemelrijck

Get full text

PIONEER’s systematic review of outcomes in RCTs of men with non-metastatic castration resistant prostate cancer: Is there a need for a core outcome set? by K. Beyer, S. MacLennan, M. Lardas, L. Moris, E. Vradi, M.I. Omar, S.J. MacLennan, A. Briganti, M. Van Hemelrijck

Get full text

A first step towards a global nomogram to predict disease progression for men on active surveillance by M. Van Hemelrijck, X. Ji, J. Helleman, M. Roobol, D. Nieboer, C. Bangma, M. Frydenberg, A. Rannikko, L-S. Lee, V. Gnanapragsam, M. Kattan

Get full text

Is it time to revise active surveillance protocols for men on active surveillance who have negative prostate findings on re-biopsy? by K. Beckmann, S. Singh, P. Sandhu, A. Santa Olalla, K. Dewan, P. Cathcart, B. Challacombe, R. Poppert, P. Dasgupta, M. Van Hemelrijck, O. Elhage

Get full text

PIONEER consensus on clinician reported outcome measurements by K. Beyer, L. Moris, G. Gandaglia, M. Lardas, J. Healey, M.I. Omar, J. Zong, S.J. Maclennan, A. Briganti, M. Van Hemelrijck, S. Maclennan

Get full text

Guy’s cancer cohort – real world evidence for cancer pathways by C. Moss, A. Haire, F. Cahill, D. Enting, S. Hughes, D. Smith, E. Sawyer, A. Davies, J. Zylstra, K. Haire, A. Rigg, M. Van Hemelrijck

Get full text

Protocol adherence and outcomes among African/Afro-Caribbean men on active surveillance for prostate cancer by K. Beckmann, H. Aya, A. Santa Olalla, P. Sandu, S. Singh, M. Nikhil, P. Cathcart, B. Challacombe, R. Poppert, P. Dasgupta, M. Van Hemelrijck, O. Elhage

Get full text

A prospective cohort study evaluating mental wellbeing in Prostate Cancer: The MIND-P Study by O. Brunckhorst, J. Liszka, C. James, J. Fanshawe, M. Hammadeh, R. Thomas, S. Khan, M. Sheriff, H. Ahmed, M. Van Hemelrijck, G. Muir, R. Stewart, K. Ahmed, P. Dasgupta

Get full text

Validation and reliability of the Dutch version of the EORTC QLQ-BLM30 module for assessing the health-related quality of life of patients with muscle invasive bladder cancer by T. M. Ripping, E. Rammant, J. A. Witjes, N. K. Aaronson, M. van Hemelrijck, L. M. C. van Hoogstraten, BlaZIB study group, L. A. Kiemeney, K. K. H. Aben

Get full text

King’s Health Partners’ Prostate Cancer Biobank (KHP PCaBB) by S. R. Saifuddin, W. Devlies, A. Santaolalla, F. Cahill, G. George, D. Enting, S. Rudman, P. Cathcart, B. Challacombe, P. Dasgupta, C. Galustian, A. Chandra, S. Chowdhury, C. Gillett, M. Van Hemelrijck

Get full text

Understanding the bladder cancer patients experience: What are the needs? by A. Bessa, C. Bosco, F. Cahill, B. Russell, L. Fox, C. Moss, H. Wylie, A. Haire, S. Green, D. Enting, S. Broadhead, M. Northover, K. Chatterton, S. Amery, N. Peat, S. Smith, C. Haggstrom, M. Van Hemelrijck

Get full text

PIONEER’s operational definitions: Harmonising clinical characteristics and phenotypes data of prostate cancer patients by K. Beyer, L. Moris, M. Lardas, G. Gandaglia, M. Roobol, A. Bjartell, M.I. Omar, R. Herrera, S. Maclennan, E. Smith, J. Zong, T. Hofmarcher, N. Zounemat Kermanin, S.J. Maclennan, A. Briganti, C. Reich, B. Meulder, M. Van Hemelrijck

Get full text

ReIMAGINE: a prostate cancer research consortium with added value through its patient and public involvement and engagement by S. Green, S. Tuck, J. Long, T. Green, A. Green, P. Ellis, A. Haire, C. Moss, F. Cahill, N. McCartan, L. Brown, A. Santaolalla, T. Marsden, M. Rodriquez Justo, J. Hadley, S. Punwani, G. Attard, H. Ahmed, C. M. Moore, M. Emberton, M. Van Hemelrijck

Get full text

Identifying the most appropriate instrument for Patient-Reported Outcome Measures (PROMs) in patients with clinically localised prostate cancer by M.M. Ratti, G. Gandaglia, L. Leardini, S. Mazzoleni Ferracini, E.S. Sisca, A. Derevianko, F. Furnari, K. Beyer, F. Pellegrino, G. Sorce, F. Barletta, S. Scuderi, M.I. Omar, S. Maclennan, J. Zong, S.J. Maclennan, O.L. Aiyegbusi, M. Van Hemelrijck, J. N’Dow, A. Briganti

Get full text

PIONEER: European Commission Innovative Medicines Initiative funded BD4BO (Big data for better outcome) project on prostate cancer by S. Evans Axelsson, T. Abbott, L. Fullwood, M.I. Omar, M. Cavelaars, A. Asiimwe, M. Roobol, M.J. Ribal, C. Auffray, Z. Devecseri, E.J. Smith, M. Van Hemelrijck, S. MacLennan, D. Horgan, C. Reich, B. De Meulder, D. Lancet, C. Bangma, A. Briganti, D. Tilki, H. Van Poppel, M.P. Wirth, J. N’Dow, A. Bjartell

Get full text